Analysis of Therapeutic and Adverse Effects of Cisplatin Chemotherapy and Different Dose Radiotherapy in Inoperable Esophageal Cancer

Abstract

The aim was to compare the efficacy and toxic side effects of different doses of radiotherapy
combined with cisplatin chemotherapy in the radical treatment of inoperable esophageal cancer. So, 100
patients with inoperable esophageal cancer admitted to our hospital from January 2017 to December 2017
were selected and divided into control group and research group by using envelope method. Both groups
received radiotherapy combined with concurrent cisplatin chemotherapy radical therapy, the control
group received high-dose radiotherapy + concurrent cisplatin chemotherapy, and the research group received low-dose + concurrent cisplatin chemotherapy. The clinical efficacy of the two groups of patients,
the occurrence status of toxic adverse reactions, the level of coagulation function indicators of the two
groups of patients, and the survival rate of the two groups of patients were compared. The clinical effect of
the study group was better than that of the control group. The overall incidence of liver and kidney injury,
bone marrow suppression, digestive tract reaction and radioactive esophagitis in the study group was lower than that in the control group (p < 0.05). The platelet count level in the treatment group was higher
than that in the control group, and the fibrinogen and d-d levels were lower than those in the control
group (p < 0.05). Survival rates at the 6th, 12th and 18th months in the study group were higher than those
in the control group (p < 0.05). In the clinical treatment of patients with inoperable esophageal cancer, the
use of low-dose radiotherapy combined with cisplatin chemotherapy for radical treatment has significant
clinical efficacy and few toxic adverse reactions. Compared with high-dose radiotherapy, the effect on the
coagulation function of patients is smaller, and the application effect is ideal, which can be considered to
be widespread